CORE: Protocol Review and Monitoring System (PRMS) PROJECT SUMMARY The Dan L. Duncan Cancer Center (DLDCC) has established the Protocol Review and Monitoring Committee (PRMC) to provide systematic internal oversight of the scientific and research aspects of all cancer-related therapeutic and prevention clinical trials conducted in DLDCC affiliated institutions. By BCM and DLDCC policy, the PRMC has authority to approve and close all DLDCC clinical research protocols. Chaired by Stacey Berg, M.D., the PRMC is organized into an Executive Committee and three working groups, with a total of 44 voting members. The PRMC assigns each protocol a scientific merit score of 1-9 according to standard NIH review descriptors. In addition, a DLDCC priority score of High, Medium, or Low is assigned to aid protocol prioritization. Studies that have been approved by the NCI Cancer Therapy Evaluation Program (CTEP) or Cancer Prevention and Control Protocol Review Committee or that are supported by an NIH funding mechanism that required full peer review as part of the funding process undergo an expedited administrative review. The PRMC also monitors progress and accrual of active studies. At the time of each open protocol?s annual IRB review, or more frequently if deemed necessary, the PRMC conducts a full review to ensure that adequate scientific progress is being made. In addition, the PRMC reviews the accrual to all the open protocols in each Program on a quarterly basis. The PRMC functions in a complementary but not duplicative way with the IRB and the Data Safety Monitoring Committees. The PRMC provides reports to the Clinical Research Leadership Committee, which also receives reports from the Data Safety Monitoring Committees, thus ensuring that activities of these two separate entitles are integrated. From 2011 to 2013, the PRMC reviewed an average of 44 new submissions per year, including 10 investigator-initiated institutional, 19 National Group, 3 other externally peer reviewed, and 12 industry sponsored protocols. An average of 140 annual reviews of ongoing progress were also performed each year.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA125123-13
Application #
9759808
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
13
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Nair, Amritha; Chung, Hsiang-Ching; Sun, Tingting et al. (2018) Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med 24:505-511
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Singh, Ramesh; Karri, Dileep; Shen, Hong et al. (2018) TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. J Clin Invest 128:3129-3143
Richards, JoAnne S; Ren, Yi A; Candelaria, Nicholes et al. (2018) Ovarian Follicular Theca Cell Recruitment, Differentiation, and Impact on Fertility: 2017 Update. Endocr Rev 39:1-20
Berntsson, Shala G; Merrell, Ryan T; Amirian, E Susan et al. (2018) Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. J Neurol 265:1432-1442
Chen, Fengju; Zhang, Yiqun; Gibbons, Don L et al. (2018) Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. Clin Cancer Res 24:2182-2193
Maldonado, Maria; Molfese, David L; Viswanath, Humsini et al. (2018) The habenula as a novel link between the homeostatic and hedonic pathways in cancer-associated weight loss: a pilot study. J Cachexia Sarcopenia Muscle 9:497-504
Kogiso, Mari; Qi, Lin; Braun, Frank K et al. (2018) Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models. Clin Cancer Res 24:2159-2170
Takahashi, Hannah; Cornish, Alex J; Sud, Amit et al. (2018) Mendelian randomisation study of the relationship between vitamin D and risk of glioma. Sci Rep 8:2339

Showing the most recent 10 out of 991 publications